In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate

British Journal of Haematology

Volumn 172, Issue 2, 2016, Pages 255-261

  Barco, Stefano ^a,b   Whitney Cheung, Y ^a   Coppens, Michiel ^a   Hutten, Barbara A ^a   Meijers, Joost C M ^a,c   Middeldorp, Saskia ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF PAVIA   (Italy)

^c SANQUIN RESEARCH   (Netherlands)

Author keywords

Anticoagulant reversal; Prothrombin complex concentrate; Prothrombin time; Rivaroxaban; Thrombin generation

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10A INHIBITOR; PROTHROMBIN COMPLEX CONCENTRATES; RIVAROXABAN; THROMBIN;

ADULT; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD CLOTTING; BLOOD CLOTTING TEST; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HUMAN; MALE; MIDDLE AGED; PROCEDURES; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADULT; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FACTOR XA INHIBITORS; HUMANS; MALE; MIDDLE AGED; PROTHROMBIN TIME; RIVAROXABAN; THROMBIN; YOUNG ADULT;

EID: 84954025591     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13821     Document Type: Article

References (28)

1. Bauersachs, R., Berkowitz, S.D., Brenner, B., Buller, H.R., Decousus, H., Gallus, A.S., Lensing, A.W., Misselwitz, F., Prins, M.H., Raskob, G.E., Segers, A., Verhamme, P., Wells, P., Agnelli, G., Bounameaux, H., Cohen, A., Davidson, B.L., Piovella, F. & Schellong, S. (2010) Oral rivaroxaban for symptomatic venous thromboembolism. The New England Journal of Medicine, 363, 2499-2510.
2. Beyer-Westendorf, J., Förster, K., Pannach, S., Ebertz, F., Gelbricht, V., Thieme, C., Michalski, F., Köhler, C., Werth, S., Sahin, K., Tittl, L., Hänsel, U. & Weiss, N. (2014) Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, 124, 955-962.
3. Bloemen, S., Hemker, H.C. & Al Dieri, R. (2013) Large inter-individual variation of the pharmacodynamic effect of anticoagulant drugs on thrombin generation. Haematologica, 98, 549-554.
4. Büller, H.R., Prins, M.H., Lensin, A.W.A., Decousus, H., Jacobson, B.F., Minar, E., Chlumsky, J., Verhamme, P., Wells, P., Agnelli, G., Cohen, A., Berkowitz, S.D., Bounameaux, H., Davidson, B.L., Misselwitz, F., Gallus, A.S., Raskob, G.E., Schellong, S. & Segers, A. (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. The New England Journal of Medicine, 366, 1287-1297.
5. Dentali, F., Marchesi, C., Pierfranceschi, M.G., Crowther, M., Garcia, D., Hylek, E., Witt, D.M., Clark, N.P., Squizzato, A., Imberti, D. & Ageno, W. (2011) Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis. Thrombosis and Haemostasis, 106, 429-438.
6. Douxfils, J., Tamigniau, A., Chatelain, B., Chatelain, C., Wallemacq, P., Dogné, J.-M. & Mullier, F. (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thrombosis and Haemostasis, 110, 723-731.
7. Eerenberg, E.S., Kamphuisen, P.W., Sijpkens, M.K., Meijers, J.C., Buller, H.R. & Levi, M. (2011) Reversal of Rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation, 124, 1573-1579.
8. Gerotziafas, G.T., Elalamy, I., Depasse, F., Perzborn, E. & Samama, M.M. (2007) In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. Journal of Thrombosis and Haemostasis, 5, 886-888.
9. Godier, A., Miclot, A., Le Bonniec, B., Durand, M., Fischer, A.-M., Emmerich, J., Marchand-Leroux, C., Lecompte, T. & Samama, C.-M. (2012) Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology, 116, 94-102.
10. Green, G., Poller, L., Thomson, J.M. & Dymock, I.W. (1976) Factor VII as a marker of hepatocellular synthetic function in liver disease. Journal of Clinical Pathology, 29, 971-975.
11. Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A.J. & Kirchhof, P. (2013) European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15, 625-651.
12. Hemker, H.C. & Béguin, S. (1995) Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thrombosis and Haemostasis, 74, 134-138.
13. Holbrook, A., Schulman, S., Witt, D.M., Vandvik, P.O., Fish, J., Kovacs, M.J., Svensson, P.J., Veenstra, D.L., Crowther, M. & Guyatt, G.H. (2012) Evidence-based management of anticoagulant therapy: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e152S-e184S.
14. Kaatz, S., Kouides, P.A., Garcia, D.A., Spyropolous, A.C., Crowther, M., Douketis, J.D., Chan, A.K.C., James, A., Moll, S., Ortel, T.L., Van Cott, E.M. & Ansell, J. (2012) Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. American Journal of Hematology, 87, S141-S145.
15. Keeling, D., Baglin, T., Tait, C., Watson, H., Perry, D., Baglin, C., Kitchen, S. & Makris, M. (2011) Guidelines on oral anticoagulation with warfarin - fourth edition. British Journal of Haematology, 154, 311-324.
16. Lauw, M.N., Coppens, M. & Eikelboom, J.W. (2014) Recent advances in antidotes for direct oral anticoagulants: their arrival is imminent. The Canadian Journal of Cardiology, 30, 381-384.
17. Levi, M., Moore, K., Castillejos, C., Kubitza, D., Berkowitz, S., Goldhaber, S., Raghoebar, M., Patel, M.R., Weitz, J. & Levy, J. (2014) Comparison of Three- and Four-Factor Prothrombin Complex Concentrates on the Anticoagulant Effects of Rivaroxaban in Healthy Volunteers. Journal of Thrombosis and Haemostasis, 12, 1428-1436.
18. Lu, G., DeGuzman, F.R., Hollenbach, S.J., Karbarz, M.J., Abe, K., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P.B., Phillips, D.R. & Sinha, U. (2013) A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nature Medicine, 19, 446-451.
19. Mueck, W., Schwers, S. & Stampfuss, J. (2013) Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thrombosis Journal, 11, 10.
20. Perlstein, I., Wang, Z., Song, Y., Wang, J., Bedford, B., Chang, M., Pursley, J., LaCreta, F., Frost, R. & Frost, C. (2014) Reversal of Apixaban Anticoagulation By 4-Factor Prothrombin Complex Concentrates in Healthy Subjects. Blood, 124, 345.
21. Pernod, G., Albaladejo, P., Godier, A., Samama, C.M., Susen, S., Gruel, Y., Blais, N., Fontana, P., Cohen, A., Llau, J.V., Rosencher, N., Schved, J.-F., de Maistre, E., Samama, M.M., Mismetti, P. & Sié, P. (2013) Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP). Archives of Cardiovascular Diseases, 106, 382-393.
22. Perzborn, E., Strassburger, J., Wilmen, A., Pohlmann, J., Roehrig, S., Schlemmer, K.-H. & Straub, A. (2005) In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor. Journal of Thrombosis and Haemostasis, 3, 514-521.
23. Perzborn, E., Gruber, A., Tinel, H., Marzec, U.M., Buetehorn, U., Buchmueller, A., Heitmeier, S. & Laux, V. (2013) Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thrombosis and Haemostasis, 110, 162-172.
24. Perzborn, E., Heitmeier, S., Laux, V. & Buchmüller, A. (2014) Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro. Thrombosis Research, 133, 671-681.
25. Samama, M.M., Guinet, C., Le Flem, L., Ninin, E. & Debue, J.-M. (2013) Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. Journal of Thrombosis and Thrombolysis, 35, 140-146.
26. Sarode, R., Milling, T.J., Refaai, M.A., Mangione, A., Schneider, A., Durn, B.L. & Goldstein, J.N. (2013) Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation, 128, 1234-1243.
27. Zahir, H., Brown, K.S., Vandell, A., Desai, M., Maa, J.-F., Dishy, V., Lomeli, B., Feussner, A., Feng, W., He, L., Grosso, M.A., Lanz, H.J. & Antman, E.M. (2015) Edoxaban Effects on Bleeding Following Punch Biopsy and Reversal by a 4-Factor Prothrombin Complex Concentrate. Circulation, 131, 81-90.
28. Zhou, W., Zorn, M., Nawroth, P., Bütehorn, U., Perzborn, E., Heitmeier, S. & Veltkamp, R. (2013) Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke, 44, 771-778.